High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2317-2322

  Cai, Qi Chun ^a   Liao, Hong ^b   Lin, Su Xia ^a   Xia, Yi ^a   Wang, Xiao Xaio ^a   Gao, Yan ^a   Lin, Ze Xiao ^c   Lu, Jia Bin ^a   Huang, Hui Qiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Jiangxi Maternal and Child Health Hospital   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

CD68; CHOP; Diffuse large B cell lymphoma; Tumor associated macrophages

Indexed keywords

CD68 ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84868003454     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0123-6     Document Type: Article

References (24)

1. Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol. 2006;43(4):213-20.
2. Coiffier B. State-of-the-art therapeutics: diffuse large B-celllymphoma. J Clin Oncol. 2005;23:6387-93.
3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-33.
4. Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive lymphoma: the international NHL prognostic factors project. N Engl J Med. 1993;329:987-94.
5. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression [J]. J Clin Oncol. 2005;23(5):953-64.
6. Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies [J]. J Pathol. 2002;196(3):254-65.
7. Mantovani A, Allavena P, Siea A, et al. Tumor-associated macrophages as a prototype type II polarized phagocyte population:role in tumor progression [J]. Eur J Cancer. 2004;40(11):1660-7.
8. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623-30.
9. Zeni E, Mazzetti L, Miotto D, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007;30(4):627-32.
10. Senapati S, Rachagani S, Chaudhary K, et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene. 2010;29(9):1293-302.
11. Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003;23(6):5015-22.
12. Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10(2):309-13.
13. Farinha P, Masoudi H, Brian F, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM)content is an independent predictor of survival in follicular lymphoma(FL). Blood. 2005;106:2169-74.
14. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-85.
15. Zhang W, Wang L, Zhou D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma. 2011;52(1):46-52.
16. Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int. 2008;58(8):529-32.
17. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11.
18. Linderoth J, Edén P, Ehinger M, Valcich J, et al. Genes associated with the tumor microenvironment are differentially expressed in cured versus primary chemotherapy -refractory diffuse large B-cell lymphoma. Br J Haematol. 2008;141(4):423-32.
19. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in Large-B-Cell Lymphomas. N Engl J Med. 2008;359(22):2313-23.
20. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065-73.
21. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin- vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784-9.
22. Canioni D, Salles G, Mounier N, Brousse N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS 2000 trail. J Clin Oncol. 2008;26(3):440-6.
23. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-Cell lymphoma treated with Rituximab. Am J Clin Pathol. 2011;135:54-61.
24. Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60:278-83.